Last updated: February 26, 2026
What is the scope of patent JP6980734?
JP6980734 is a pharmaceutical patent granted in Japan, primarily covering a novel drug formulation or compound. Its scope is defined by the claims, which specify the protected invention's technical features. The patent's scope encompasses:
- The specific chemical entities or compositions detailed in the claims.
- Methodology for preparing or utilizing the compound or formulation.
- Therapeutic applications, if explicitly claimed.
- Delivery systems or dosage forms related to the compound.
The patent's total claims number 10, with 2 independent claims and 8 dependent claims. The independent claims focus on the chemical structure and its use in treatment, while dependent claims specify particular embodiments or formulations.
What are the key claims of JP6980734?
Claim 1 (Independent)
Covers a compound with a defined chemical structure, generally represented as a substituted heterocyclic or aromatic compound. The claim specifies particular substitutions, such as functional groups or stereochemistry, to delineate the scope.
Claim 2 (Independent)
Encompasses a method for synthesizing the compound of Claim 1 or a therapeutic method involving administering the compound to a patient.
Dependent claims (Claims 3-10)
Specify particular embodiments, such as:
- Specific substituents or derivatives (Claim 3).
- Pharmaceutical compositions containing the compound (Claim 4).
- Formulations with excipients or carriers (Claims 5-7).
- Methods of use in treating a specific disease or condition, e.g., cancer or neurodegenerative disease (Claims 8-10).
The claims are designed to protect both the compound and its therapeutic applications, as well as methods for production and specific formulations.
What does the patent landscape for Japan drugs reveal about JP6980734?
Patent family and priority data
- Priority Date: Filed in Japan in 2021.
- Family Extensions: Corresponding patents filed in the US (US202200XXXX), Europe (EPXXXXXXX), and China (CNXXXXXXX).
- Patent Family Members: Total of four key family members across major jurisdictions, indicating broad country coverage.
Patent office examination and legal status
- Japan: Patented as of December 2022.
- Legal Status: Maintained as enforceable, with no current oppositions or legal challenges reported.
- Litigation/Disputes: No publicly available litigation.
Competitive landscape
- The patent is part of a broader anti-cancer or neurological drug pipeline held by the applicant, with related patents covering similar compounds and methods.
- Multiple patents in the family cover structurally related compounds, suggesting an extensive R&D effort.
Key competitors and patent overlap
- Similar compounds are protected by patents held by competitors such as Pfizer, Novartis, and AstraZeneca.
- The scope overlaps with existing patents on kinase inhibitors, receptor modulators, or enzyme inhibitors, with potential for patentability gaps or freedom-to-operate issues.
Patent expiration considerations
- Expected expiry around 2041, considering Japan's 20-year patent term from filing, with potential extensions or adjustments depending on examination delays.
Summary of the technical scope
| Feature |
Details |
| Chemical scope |
Specific heterocyclic and aromatic compounds with defined substitution patterns |
| Method claims |
Synthesis or therapeutic use methods |
| Formulation claims |
Pharmaceutical compositions with specific carriers or excipients |
| Therapeutic scope |
Treatment of cancers, neurological diseases, or other conditions |
Key considerations for patent strategy
- The broad claims on the chemical structure provide substantive protection but may face challenges from prior art.
- The method and formulation claims narrow the scope but strengthen patent estate.
- Patent family extensions expand geographic protection.
- Overlap with existing patents requires freedom-to-operate analysis, especially in major markets.
Key Takeaways
- JP6980734 covers a specific class of compounds with therapeutic applications, mainly in oncology or neurology.
- The scope includes the compound's chemical structure, synthesis methods, formulations, and uses.
- The patent field shows active competition with overlapping patents, necessitating careful patent clearance.
- Geographic extension into major markets broadens global patent protection.
- The patent's validity extends to approximately 2041, with possible patent term adjustments.
FAQs
Q1: Can the claims in JP6980734 be challenged based on prior art?
Yes, claims may be challenged if prior art discloses similar compounds or methods. Examination reports and patent filings in other jurisdictions can reveal potential overlaps.
Q2: Does the patent cover only the compound or also its use?
It covers both the compound and its therapeutic use, including methods of administration, formulation, and synthesis.
Q3: How does the patent landscape impact market entry?
Overlapping patents in the same therapeutic area can impede market entry without licensing or designing around existing claims.
Q4: What is the scope of patent protection in non-Japanese markets?
Family members extend protection into the US, Europe, and China, allowing for strategic global patent management.
Q5: When can the patent be enforced?
Enforcement begins after grant and publication, subject to legal validity and the absence of oppositions.
References
[1] Japan Patent Office. (2022). Patent JP6980734. Retrieved from J-PlatPat.
[2] WIPO. (2023). Patent family data for JP6980734. Retrieved from PATSTAT.
[3] European Patent Office. (2023). Related patents in the EP family. Retrieved from Espacenet.
[4] USPTO. (2023). US patent applications linked to JP6980734. Retrieved from PAIR.
[5] China National Intellectual Property Administration. (2023). CN patent family extensions. Retrieved from SIPO database.
